Recruiting

Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients

The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients. This study will help in understanding the interindividual variability in the CES1 gene and the effect of a single nucleotide polymorphism in this gene (rs2244613) on capecitabine-induced toxicity in participants already taking capecitabine-based chemotherapy as part of their regular medical care.

I'm interested View official listing
ClinicalTrials.gov IDNCT06765252
PhaseNot Applicable
Enrollment80
SponsorAin Shams University
Age18 Years and older
SexALL
I'm interested View official listing

Conditions studied

Colorectal Cancer, Breast Cancer

About this study

The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients. This study will help in understanding the interindividual variability in the CES1 gene and the effect of a single nucleotide polymorphism in this gene (rs2244613) on capecitabine-induced toxicity in participants already taking capecitabine-based chemotherapy as part of their regular medical care.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Patients with breast or colorectal cancer receiving capecitabine-based chemotherapy * Age \> 18 years * ECOG PS 0-2. Exclusion Criteria: * Patients treated with irinotecan * Lack of physical integrity of the upper gastrointestinal tract * Patients with malabsorption syndrome * Patients having inability to take oral medication * Patients with poor performance status * Patients with chronic diarrhea as ulcerative colitis or Crohn's disease

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-17.